Allyx Therapeutics is a clinical stage biotech company focused on developing a novel oral drug therapy for Alzheimer’s disease and other neurodegenerative diseases. Our lead drug program ALX-001 (BMS-984923) offers a promising approach to protect and restore dysfunctional and lost synapses in the brain. Allyx is currently launching a Phase 2 clinical trial to provide clinical proof of concept in Alzheimer’s disease patients.
Intensity is a late-stage clinical biotechnology company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumor’s dense, high-fat, pressurized environment following direct intratumoral injection. As a result of the saturation, Intensity’s clinical trials have demonstrated the ability of INT230-6 to kill tumors and elicit an adaptive immune response within days of injection, representing a new approach to cancer cell death that holds the potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases even for malignancies that do not respond to conventional chemotherapy or immunotherapy.
Research Activities:
Intensity has completed two clinical studies that enrolled over 200 patients using INT230-6: a Phase 1/2 dose escalation study in metastatic cancers including sarcomas (NCT03058289), and a Phase 2 randomized control clinical trial in locally advanced breast cancer (the “INVINCIBLE-2 Study”) (NCT04781725) in women without undergoing chemotherapy prior to their surgery. The Company initiated a Phase 3 trial in soft tissue sarcoma (the “INVINCIBLE-3 Study”) (NCT06263231), testing INT230-6 as second or third-line monotherapy compared to the SOC with overall survival as an endpoint. Intensity also initiated a Phase 2 study in collaboration with The Swiss Group for Clinical Cancer Research, formerly SAKK, now the Swiss Cancer Institute (the “INVINCIBLE-4 Study”) (NCT06358573) as part of a Phase 2/3 program evaluating INT230-6 followed by the SOC immunochemotherapy and the SOC alone for patients with presurgical triple-negative breast cancer. The pathological complete response rate is the endpoint.
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. We provide contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. Our goal is to be a trusted source for all your assay development and manufacturing needs.
Formed in 2022 to develop a sTNFR2 lateral flow device for screening febrile children for Kawasaki Disease with additional uses in resource challenged settings. Mothballed at the end of 2024 when the USA pulled out of the WHO. In summer of 2026 Saga Bio will spin back up as a virtual biotech to develop biotherapeutics and a modified “dead” Fc domain critical for biotherapeutic TNFR2 blockade. Saga Bio has right of first refusal for Johnson/Yale IP. In 2024 Saga received a Blavatnik Award to develop biotherapeutic antibodies against Tmem 273.
Pipeline:
1) Tmem 273 biotherapeutic antibody hc10-6g1 coupled to monomethyl auristatin e (ADC). Tmem 273 is a unique yes/no biomarker for T cells that co-produce IFN-gamma and IL-13 and drive fibrosis in disease including systemic sclerosis and chronic asthma. Biotherapeutic strategy based on depleting Tmem 273 positive T cells. First human investigation of Tmem 273 as a biomarker will be submitted June 2026.
2) TNFR2 biotherapeutic 26C9antibody with an Fc-dead domain. Blocks membrane TNFalpha binding to TNFR2 and alters cytokine profile to a tolerogenic pattern. Likely able to induce tolerance in transplant and autoimmunity.
Research Activities:
Saga Bio will manage CRO research activities when pipeline projects transition from the academic realm to biotech.
Precision Biotools offers an antibody discovery service that begins with the epitope. Through its proprietary EPISOLVE, EPIVOLVE and SUNDAE platforms Precision Biotools engineers immunogenicity into epitopes precisely at the target site and nowhere else. Precision Biotools delivers antibodies and antibody-like scaffolds with high specificity and verified activity in real-world biology setting where all other antibody discovery techniques fail.
I work at the intersection of People, Strategy, and Performance—helping leaders and organizations navigate complexity and translate ambition into measurable results.
With 20+ years of experience, including leadership roles at Pfizer & as founder of The Possibility Experience, I partner with executive teams to lead transformation across large-scale initiatives, M&A, workforce capability, & organizational effectiveness.
My work focuses on four core areas:
At the core of my work is a deeply held belief:
People are the most critical asset of any organization—and when invested in intentionally, they are the greatest driver of sustainability.
Trusted by over 1,000 customers worldwide, SciSure is an award-winning Scientific Management Platform (SMP) that unifies ELN, LIMS, EHS, and integrations into a single solution. Formed through the merger of SciShield and eLabNext, SciSure brings together decades of expertise in lab digitization and compliance. Recognized for product innovation and customer satisfaction, SciSure supports scientists, lab operations, and compliance teams in delivering operational excellence and research integrity.
Pacific Marine Biotech (PMB) founded in 2022 and headquartered in Torrington, Connecticut, with additional operations in Brisbane, Australia.
The company is focused on developing innovative, marine-derived therapies for difficult-to-treat cancers, particularly glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). Its lead investigational product, Immune12, is a proprietary complex biologic derived from marine organisms and designed to modulate immune response and exhibit potential anti-tumor activity.
Pacific Marine Biotech’s research program includes extensive preclinical studies, where Immune12 has demonstrated anti-cancer activity in vitro and in vivo, including tumor growth inhibition and a favorable safety profile in animal models.
Building on these findings, the company is advancing clinical development, including Phase 2 GBM 60 patient trials in Australia evaluating Immune12 in patients with high-grade gliomas. These studies aim to assess safety, efficacy, tumor response, and quality-of-life outcomes while supporting regulatory pathways toward FDA approval.
Through its integrated research and clinical strategy, PMB seeks to bring a novel, low-toxicity biologic therapy to patients with limited treatment options, leveraging marine biotechnology to address unmet needs in oncology.
At Linde, we provide critical gases and cryogens that sustain daily operations for our pharmaceutical and biotechnology customers. From research and development through scale-up and into full production, we have the gases you need in the way you need them.
Linde’s experience goes well beyond gas supply. Our advanced application expertise in gas-liquid mixing and temperature-control engineering can help you achieve the process reliability, drug uniformity, product quality and cost savings you need to make the world a healthier place. So whether you’re tasked with drug discovery, process development, manufacturing, quality control, cell preservation or any other facet of the industry, Linde’s broad gas portfolio (GMP and non-GMP), application innovation and supply distribution will help control the process, so you can focus on finding the cure.
Connecticut Children’s is the only health system in Connecticut 100% dedicated to kids. That means high-quality care across more than 30 pediatric specialties in 30+ locations throughout Connecticut, Eastern New York and Western Massachusetts. One team on a mission to improve access to healthcare from before birth and into adulthood. One team pushing the limits with breakthrough research and community partnerships so we can help you focus on what matters most: your family’s wellness journey. When you choose Connecticut Children’s, you can expect care beyond imagination.
Research Activities:
Connecticut Children’s Research Institute (CCRI) is at the forefront of transforming pediatric healthcare. We stand at the intersection of passion and innovation, driven by a mission to revolutionize the care and treatment of children, offering new hope for better outcomes. Our commitment to advancing medical science and addressing the social drivers of health fuels our pursuit of solutions for children and families, particularly in underexplored and underserved areas.
Our Research Institute combines our unique expertise across five Scientific Centers featuring physician scientists who collaborate with premier research partners in our region such as UConn Health and The Jackson Laboratory, as well as clinical investigators and other scholars from around the world.
As leaders in developing breakthrough therapies for children with a variety of medical conditions, our work ranges from investigating fetal growth restriction to advancing personalized cancer treatments. We improve children’s health through clinical, basic, and translational research, with an emphasis on mental health and addressing healthcare gaps. This ensures a holistic approach for the whole child.
Connecticut Children’s is the only health system in Connecticut 100% dedicated to kids. That means high-quality care across more than 30 pediatric specialties in 30+ locations throughout Connecticut, Eastern New York and Western Massachusetts. One team on a mission to improve access to healthcare from before birth and into adulthood. One team pushing the limits with breakthrough research and community partnerships so we can help you focus on what matters most: your family’s wellness journey. When you choose Connecticut Children’s, you can expect care beyond imagination.
Research Activities:
Connecticut Children’s Research Institute (CCRI) is at the forefront of transforming pediatric healthcare. We stand at the intersection of passion and innovation, driven by a mission to revolutionize the care and treatment of children, offering new hope for better outcomes. Our commitment to advancing medical science and addressing the social drivers of health fuels our pursuit of solutions for children and families, particularly in underexplored and underserved areas.
Our Research Institute combines our unique expertise across five Scientific Centers featuring physician scientists who collaborate with premier research partners in our region such as UConn Health and The Jackson Laboratory, as well as clinical investigators and other scholars from around the world.
As leaders in developing breakthrough therapies for children with a variety of medical conditions, our work ranges from investigating fetal growth restriction to advancing personalized cancer treatments. We improve children’s health through clinical, basic, and translational research, with an emphasis on mental health and addressing healthcare gaps. This ensures a holistic approach for the whole child.